|
May 10
|
Evaxion Receives Nasdaq Notification
|
|
May 7
|
Sidoti Events, LLC's Virtual May Micro-Cap Conference
|
|
Apr 17
|
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01
|
|
Apr 3
|
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
|
|
Apr 3
|
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript
|
|
Apr 2
|
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection
|
|
Mar 27
|
Evaxion Announces Business Update and Full Year 2023 Financial Results
|
|
Mar 22
|
When Will Evaxion Biotech A/S (NASDAQ:EVAX) Turn A Profit?
|
|
Mar 19
|
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
|
|
Dec 21
|
Evaxion Biotech Announces Closing of Private Placement
|
|
Dec 19
|
Evaxion Announces Business Update and Third Quarter 2023 Financial Results
|
|
Dec 19
|
Evaxion Biotech Announces Private Placement Financing
|
|
Nov 28
|
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
|
|
Nov 6
|
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
|
|
May 25
|
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
|
|
May 25
|
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
|